H
BIO icon

Hexavest’s Bio-Rad Laboratories Class A BIO Stock Holding History

Hexavest’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$5.99M Sell
8,031
-1,616
-17% -$1.21M 0.37% 98
2021
Q2 		$6.21M Sell
9,647
-2,344
-20% -$1.43M 0.31% 112
2021
Q1 		$6.85M Sell
11,991
-2,175
-15% -$1.29M 0.3% 116
2020
Q4 		$8.26M Sell
14,166
-8,522
-38% -$4.85M 0.31% 107
2020
Q3 		$11.7M Sell
22,688
-3,200
-12% -$1.62M 0.31% 111
2020
Q2 		$11.7M Buy
25,888
+25,867
+123,176% +$11.4M 0.27% 108
2020
Q1 		$7K Buy
+21
New +$7.72K ﹤0.01% 415

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Hexavest's BIO Position: Q3 2021 in Review

Hexavest reduced its Bio-Rad Laboratories Class A (BIO) stake by 17% in Q3 2021, selling an estimated $1.21M and leaving 8,031 shares worth $5.99M. The position accounts for 0.37% of the portfolio, ranked #98.

Hexavest first reported a position in BIO in Q1 2020 and has held it in 7 quarters since. The position peaked at $11.7M in Q3 2020. 508 funds tracked by Wall St. Rank hold BIO as of Q3 2021.

  • Hexavest held 8,031 shares of Bio-Rad Laboratories Class A worth $5.99M as of Q3 2021.
  • Hexavest sold 1,616 Bio-Rad Laboratories Class A shares in Q3 2021, an estimated $1.21M.
  • Bio-Rad Laboratories Class A made up 0.37% of Hexavest's portfolio in Q3 2021, its #98 holding.
  • Hexavest first reported a position in Bio-Rad Laboratories Class A in Q1 2020 and has held it in 7 quarters since.
  • Hexavest's Bio-Rad Laboratories Class A position peaked at $11.7M in Q3 2020.
  • 508 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2021.

Based on Hexavest's 13F filing for Q3 2021, filed 27 Oct 2021.